Menu
Homer Pien has an impressive background with experience in leading positions at organisations such as Philips, Massachusetts General Hospital, Harvard Medical School, and several start-up companies. He has chosen to engage with SpectraCure’s board because he believes there is a significant need for individualised prostate cancer treatments. The way SpectraCure conducts prostate cancer treatment with photodynamic therapy enables this, and Homer sees that SpectraCure can contribute something unique. He possesses a strong understanding of the transition from research to commercialisation and strives to contribute to SpectraCure’s success.
If you’re curious to learn more about Homer Pien and what he considers unique about SpectraCure, don’t miss the opportunity to watch the entire interview!
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.